Landmark Study: Six-Year Data Confirm Durable Benefit of Combination Immunotherapy in Advanced Lung Cancer
Table of Contents
A new analysis of the CheckMate 9LA trial demonstrates sustained long-term survival benefits for patients with metastatic non-small cell lung cancer (NSCLC) treated with nivolumab (opdivo) and ipilimumab (Yervoy) plus chemotherapy, particularly those with low PD-L1 expression.
The final analysis, published in ESMO Open on May 29, 2025, with a minimum follow-up of 68.6 months, reinforces earlier findings and establishes the combination regimen as a highly effective standard of care for first-line treatment. This data provides compelling evidence of lasting benefit, even after treatment cessation, offering renewed hope for patients facing this aggressive disease.
CheckMate 9LA: A Study Design Overview
CheckMate 9LA was a global, randomized, open-label phase 3 study involving 719 adults newly diagnosed with stage IV or recurrent NSCLC without specific genetic alterations (EGFR or ALK). Participants were randomly assigned to receive either nivolumab plus ipilimumab alongside two cycles of platinum-doublet chemotherapy, or chemotherapy alone for four cycles. The combination therapy leverages two distinct immunotherapy agents – nivolumab, which targets the PD-1 pathway, and ipilimumab, which inhibits CTLA-4 – to stimulate a more robust immune response against cancer cells. Patients receiving immunotherapy could continue treatment for up to two years,and those with nonsquamous NSCLC in the chemotherapy arm were eligible for optional pemetrexed maintenance therapy.
Initial results, published in The Lancet Oncology in february 2021, showed a 34% overall survival (OS) benefit with the combination therapy after a median follow-up of 13.2 months.
Sustained Long-Term Benefit Demonstrated After Six Years
The latest data reveals that the combination of nivolumab, ipilimumab, and chemotherapy delivered a 26% overall survival (OS) benefit over six years compared to chemotherapy alone. At a median follow-up of 75.8 months, the hazard ratio (HR) for OS was 0.74 (95% confidence interval [CI], 0.63-0.87), translating to 6-year OS rates of 16% versus 10%. This benefit remained consistent across most patient subgroups, regardless of tumor histology.
Notably, patients with squamous NSCLC experienced a more pronounced benefit, with 6-year OS rates of 14% with the combination versus 5% with chemotherapy alone (HR, 0.65; 95% CI, 0.49-0.85). This is particularly significant, as squamous NSCLC often presents with limited treatment options and a poorer prognosis.For patients with nonsquamous histology, 6-year OS rates were 17% versus 12% (HR, 0.79; 95% CI, 0.65-0.96).
Breakthrough for PD-L1 Negative Patients
Perhaps the most encouraging finding lies within the subgroup of patients with tumors expressing low levels of PD-L1 (less than 1%). Historically, these patients have been challenging to treat with single-agent PD-1/PD-L1 inhibitors, as their tumors don’t readily display the PD-L1 protein, which is the target of these therapies. However, the CheckMate 9LA data demonstrate a significant survival advantage with the combination of nivolumab and ipilimumab plus chemotherapy, even in this historically difficult-to-treat population.
A New Standard of Care for Metastatic NSCLC
The authors conclude that the 6-year CheckMate 9LA data firmly establish nivolumab plus ipilimumab with chemotherapy as a highly effective first-line treatment option for metastatic NSCLC. The regimen’s ability to deliver durable benefits across diverse patient subgroups, especially those with low PD-L1 expression and squamous histology, represents a significant advancement in the fight against this challenging cancer.
“These results further support nivolumab plus ipilimumab with chemotherapy as an efficacious standard-of-care first-line treatment option for patients with metastatic NSCLC,” the study authors assert. The long-term durability of response highlights the potential for lasting immunological memory and improved quality of life for patients battling this disease.
Worth a look
